Stock Evaluator: Quoin Pharmaceuticals, Ltd. (QNRX)

Quoin Pharmaceuticals, Ltd. QNRX

$6.90 0.10 1.47%
September 16, 2026 4:00:00 PM EST November 10, 2021 Volume: 52,125
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Quoin Pharmaceuticals, Ltd., a late-stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases in the United States. The company’s lead product is QRX003, a topical lotion, which is in phase 2 to treat netherton syndrome (NS); phase 1 in to treat peeling skin syndrome; and in pre-clinical stage to treat SAM syndrome and ichthyosis. It also develops QRX008 for the treatment of scleroderma, which is in pre-clinical stage; and QRX009, to treat microcystic lymphatic malformations, venous malformations, angiofibroma, and other diseases. It has a research agreement with Queensland University of Technology. Quoin Pharmaceuticals, Ltd. was founded in 2018 and is based in Ashburn, Virginia. Quoin Pharmaceuticals, Ltd. is a subsidiary of Skinvisible, Inc.

Commentary & Analysis


Financial Summary

Share Statistics QNRX Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $13.7 $262.9 8%
Shares Out (Mil) 2.8 54.4 10%
Institutional Ownership 81.5% 92.9% 50%
Float (Mil) 1.3 41.5 3%
Beta 1.66 0.94 86%
Avg Daily Volume (000s) 157 496 42%
Price Change
(52-week)
(10.5%) 54.5% 41%
Growth QNRX Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 14.1% na
Net Income (5yr) (49.7%) (10.1%) 7%
EPS (5yr) na 15.8% na
Dividends (5yr) na 0.0% na
Cash Flow (5yr) na (15.6%) na
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 2 2 2
Current EPS ($1.760) ($7.170) ($3.185)
Month Ago EPS ($2.050) ($7.890) ($2.910)
# Rev Up 0 1 0
# Rev Down 1 0 1
Three Months Ago EPS ($1.685) ($6.880) ($2.910)
Year/Year Chg (7.2%) (51.5%) (94.0%)
Financials QNRX Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $37 na
Net Income (TTM) (Mil) ($19) ($43) 24%
EPS (TTM) ($8.521) ($1.500) 5%
Operating Cash Flow (TTM) (Mil) ($15) ($31) 17%
Net Cash Flow (TTM) (Mil) $2 $2 48%
Long-Term Debt (Q1) (Mil) $1 $4 18%
Enterprise Value (Q1) (Mil) $2 $179 4%
Valuation QNRX Industry
Median
Percentile
(All Stocks)
P/B 3.47 2.56 70%
P/E na 18.8 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 1.0 na
Ratios QNRX Industry
Median
Percentile
(All Stocks)
Gross Margin na 68.2% na
Net Margin na (73.0%) na
ROA (178.8%) (47.9%) 2%
ROE (575.7%) (55.0%) 1%
Liabilities to Assets 67.1% 29.4% 63%
F-Score 1 2 1%

Quoin Pharmaceuticals, Ltd. did not pass any screens on 9/15/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors